{"id":5068,"date":"2022-02-09T08:26:31","date_gmt":"2022-02-09T08:26:31","guid":{"rendered":"https:\/\/medical.ezag.com\/?post_type=news&#038;p=5068"},"modified":"2022-04-14T07:15:14","modified_gmt":"2022-04-14T07:15:14","slug":"eckert-ziegler-to-supply-telix-with-lutetium-177-for-clinical-trials","status":"publish","type":"news","link":"https:\/\/medical.ezag.com\/en\/news\/eckert-ziegler-to-supply-telix-with-lutetium-177-for-clinical-trials\/","title":{"rendered":"Eckert &#038; Ziegler to Supply Telix with Lutetium-177 for Clinical Trials"},"content":{"rendered":"<section class='mx-auto w-full inline-block'>\n\t\t\t\t    <div class='mx-auto w-full bg-gray-c_bright2 md:pt-4 md:min-h-c_lg1'>\n\t\t\t\t        <div class='max-w-5xl mx-auto overflow-hidden'>\n\t\t\t\t            <div class='float-none md:float-right w-full md:w-c_p30 max-h-64 md:h-auto mx-auto md:mx-0 mt-0 pt-0 md:pt-12 px-0 pb-0 md:pb-4 overflow-hidden'>\n\t\t\t\t            \t<img loading='lazy' class='w-full h-full max-h-64 object-cover object-cover object-center' src='https:\/\/medical.ezag.com\/wp-content\/uploads\/2022\/01\/Telix.png' alt=''>\n\t\t\t\t            <\/div>\n\t\t\t\t            <div class='md:flex md:flex-col md:justify-end float-none md:float-left md:min-h-c_lg1 w-full md:w-c_p69 mx-4 md:mx-0 py-10 md:py-0 md:pb-14 pr-0 md:pr-4'>\n\t\t\t\t            \t<h1 class='font-bold text-blue-100 text-c_lg2'>Eckert &#038; Ziegler to Supply Telix with Lutetium-177 for Clinical Trials<\/h1>\n\t\t\t\t            <\/div>\n\t\t\t\t        <\/div>\n\t\t\t\t    <\/div>\n\t\t\t\t<\/section><div class='mx-auto w-full bg-white px-4 md:px-0 pt-8 md:pt-0'>\n\t\t\t    \t\t<div class='container max-w-5xl mx-auto'>\n\t\t        \t\t<p class='text-c_sm font-bold md:mb-c_B_xs2'>February 9, 2022 | Berlin<\/p><\/div><\/div>\n\n\n\t\t<section  class='mx-auto w-full bg-white px-4 md:px-0 pt-8 md:pt-0'>\n\t\t\t<div class='container max-w-5xl mx-auto mb-c_B_big'>\n\t\t\t\t\n\n\t\t\t<p class='text-c_md5 font-semibold mb-c_B_xs2'>Eckert &amp; Ziegler to Supply Telix with Lutetium-177 for Clinical Trials<\/p>\n\t\t\t<div class='text-c_md2 mb-10' >\n\t\t\t\t\n\n<p>Berlin, 9 February 2022. Eckert &amp; Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert &amp; Ziegler&#8217;s therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix&#8217;s portfolio of Molecularly Targeted Radiation (MTR) investigational products.<\/p>\n<p>EZAG will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix&#8217;s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer).<\/p>\n<p>Lutetium-177 is used in precision oncology for targeted radionuclide therapy. The radioisotope Lutetium-177, is linked to tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells, while largely sparing healthy tissue.<\/p>\n<p>&#8220;The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services,&#8221; explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert &amp; Ziegler. &#8220;Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.&#8221;<\/p>\n<p>Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, &#8220;We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who are now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix&#8217;s relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.&#8221;<\/p>\n<p>Radiotherapeutic agents that are coupled with Lutetium-177 prior to injection are currently under late-stage clinical development for several types of cancer.<\/p>\n<p><strong>About Eckert &amp; Ziegler.<\/strong><br \/>Eckert &amp; Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world&#8217;s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert &amp; Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B\u00f6rse.<br \/><strong>Contributing to saving lives.<\/strong><\/p>\n<p><strong>About Telix Pharmaceuticals<\/strong><br \/>Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).<\/p>\n<p><b>Contact:<\/b><br \/><b>Eckert &amp; Ziegler AG<\/b><br \/>Karolin Riehle, Investor Relations<br \/>Robert-R\u00f6ssle-Str. 10, 13125 Berlin, Germany<br \/>Tel.: +49 (0) 30 \/ 94 10 84-138,\u00a0<a href=\"mailto:karolin.riehle@ezag.de\" target=\"_blank\" rel=\"noopener\">karolin.riehle@ezag.de<\/a>,\u00a0<a href=\"https:\/\/eqs-cockpit.com\/cgi-bin\/fncls.ssp?fn=redirect&amp;url=f8525ca55295fb1907527afac25224be&amp;application_id=1278053&amp;site_id=news_data&amp;application_name=news\" target=\"_blank\" rel=\"noopener\">www.ezag.com<\/a><br \/><b>Telix Pharmaceuticals:<\/b><br \/>Dr. Stewart Holmstrom, Corporate Communications<br \/>Suite 401, 55 Flemington Road, North Melbourne, VIC 3051, Australia<br \/><a href=\"mailto:stewart.holmstrom@telixpharma.com\" target=\"_blank\" rel=\"noopener\">stewart.holmstrom@telixpharma.com<\/a>,\u00a0<a href=\"https:\/\/eqs-cockpit.com\/cgi-bin\/fncls.ssp?fn=redirect&amp;url=c494520bfc540d23498d13878d15e5ba&amp;application_id=1278053&amp;site_id=news_data&amp;application_name=news\" target=\"_blank\" rel=\"noopener\">www.telixpharma.com<\/a><\/p>\n\n\n\t\t\t<\/div>\n\t\n\n\t\t\t<\/div>\n\t\t<\/section>\n\t\n\n\n\t\t<div class='items-center justify-center newsletter-overlay' id='newsletter_modal'>\n\t\t\t<div class='w-full max-w-5xl max-h-screen overflow-y-scroll rounded px-10 py-10 flex flex-col relative' style='background: #F9F9F9;'>\n\t\t\t\t<button class='absolute top-0 right-0 pt-6 pr-4' id='newsletter_modal_close'>\n\t\t\t\t\t<svg width='30' height='20' viewBox='0 0 54 56' version='1.1' xmlns='http:\/\/www.w3.org\/2000\/svg' xmlns:xlink='http:\/\/www.w3.org\/1999\/xlink'>\n                        <g id='Page-1' stroke='none' stroke-width='1' fill='none' fill-rule='evenodd'>\n                            <g id='Artboard' transform='translate(-371.000000, -111.000000)' fill='#383139'>\n                                <path d='M378.70101,113.251263 L398.08503,132.635243 L416.884776,113.837049 C418.642136,112.07969 421.491378,112.07969 423.248737,113.837049 C425.006097,115.594408 425.006097,118.443651 423.248737,120.20101 L404.44903,138.999243 L423.248737,157.79899 C425.006097,159.556349 425.006097,162.405592 423.248737,164.162951 C421.491378,165.92031 418.642136,165.92031 416.884776,164.162951 L398.08503,145.363243 L378.70101,164.748737 C376.943651,166.506097 374.094408,166.506097 372.337049,164.748737 C370.57969,162.991378 370.57969,160.142136 372.337049,158.384776 L391.72203,138.999243 L372.337049,119.615224 C370.57969,117.857864 370.57969,115.008622 372.337049,113.251263 C374.094408,111.493903 376.943651,111.493903 378.70101,113.251263 Z' id='Combined-Shape'\/>\n                            <\/g>\n                        <\/g>\n                    <\/svg>\n\t\t\t\t<\/button>\n\t\t\t\t<span class='text-3xl font-bold text-gray-c_dark3 mb-2'>The Medical Bulletin<\/span>\n\t\t\t\t<span class='text-2xl text-gray-c_dark3 mb-4'>Subscribe and stay updated<\/span>\n\t\t\t\t<p class='text-xl text-gray-c_dark3 mb-10 font-light'>\n\t\t\t\t\tAre you interested in receiving the latest news on our products and recent developments? Do you want to stay updated regarding upcoming events? Our newsletter will be sent regularly and you can unsubscribe anytime.\n\t\t\t\t<\/p>\n\t\t\t\t<div id='newsletter-progress' class='hidden h-full w-full min-h-96'>\n\t\t\t\t<\/div>\n\t\t\t\t<form method='POST' id='newsletter-signup' name='newsletter-signup'>\n\t\t\t\t    <input type=\"hidden\" id=\"newsletter_nonce\" name=\"newsletter_nonce\" value=\"5a063c4b31\" \/><input type=\"hidden\" name=\"_wp_http_referer\" value=\"\/en\/wp-json\/wp\/v2\/news\/5068\" \/>\n\t\t\t\t   <input type='hidden' name='referrer' value='https:\/\/medical.ezag.com\/en\/news\/eckert-ziegler-to-supply-telix-with-lutetium-177-for-clinical-trials\/'>\n\t\t                <div class='flex flex-col text-c_sm'>\n\t\t                \t<div class='w-full flex-grow-0 mb-4'>\n\t\t                            <input id='newsletter_id_input' type='text' name='email' placeholder='Email*' class='w-full !outline-none p-c__md1 border-c_0.3 border-solid border-black box-border rounded-5' required=''>\n\t\t                    <\/div>\n\t\t                \n\t\t                    <div class='w-full flex space-x-4 mb-3.5'>\n\t\t                       <div class='w-1\/2 flex-grow-0'>\n\t\t                            <input type='text' name='first_name' placeholder='First Name*' class='w-full !outline-none p-c__md1 border-c_0.3 border-solid border-black box-border rounded-5' required=''>\n\t\t                    \t<\/div>\n\t\t                        <div class='w-1\/2 flex-grow-0'>\n\t\t                            <input type='text' name='last_name' placeholder='Last Name*' class='w-full !outline-none p-c__md1 border-c_0.3 border-solid border-black box-border rounded-5' required=''>\n\t\t                        <\/div>\n\t\t                    <\/div>\n\t\t\n\t\t\t\t\t\t\t<div class='w-full flex space-x-4 mb-4'>\n\t\t                       <div class='w-1\/2 flex-grow-0'>\n\t\t                            <input type='text' name='job' placeholder='Job Title' class='w-full !outline-none p-c__md1 border-c_0.3 border-solid border-black box-border rounded-5'>\n\t\t                    \t<\/div>\n\t\t                        <div class='w-1\/2 flex-grow-0'>\n\t\t                            <input type='text' name='company' placeholder='Company*' class='w-full !outline-none p-c__md1 border-c_0.3 border-solid border-black box-border rounded-5' required=''>\n\t\t                        <\/div>\n\t\t                    <\/div>\n\t\t                    \n\t\t                    <select id='country' name='country' required='' class='mt-1 block w-full mb-4 pl-3 pr-10 py-2 focus:outline-none w-full !outline-none p-c__md1 border-c_0.3 border-solid border-black box-border sm:!text-lg rounded-5'><\n\t\t                    <option value='default'>Choose your country<\/option>\n\t\t\t\t\t\t\t    <option value='AF'>\n\t\t\t\t\t\tAfghanistan\n\t\t\t\t\t<\/option><option value='AX'>\n\t\t\t\t\t\tAland Islands\n\t\t\t\t\t<\/option><option value='AL'>\n\t\t\t\t\t\tAlbania\n\t\t\t\t\t<\/option><option value='DZ'>\n\t\t\t\t\t\tAlgeria\n\t\t\t\t\t<\/option><option value='AS'>\n\t\t\t\t\t\tAmerican Samoa\n\t\t\t\t\t<\/option><option value='AD'>\n\t\t\t\t\t\tAndorra\n\t\t\t\t\t<\/option><option value='AO'>\n\t\t\t\t\t\tAngola\n\t\t\t\t\t<\/option><option value='AI'>\n\t\t\t\t\t\tAnguilla\n\t\t\t\t\t<\/option><option value='AQ'>\n\t\t\t\t\t\tAntarctica\n\t\t\t\t\t<\/option><option value='AG'>\n\t\t\t\t\t\tAntigua and Barbuda\n\t\t\t\t\t<\/option><option value='AR'>\n\t\t\t\t\t\tArgentina\n\t\t\t\t\t<\/option><option value='AM'>\n\t\t\t\t\t\tArmenia\n\t\t\t\t\t<\/option><option value='AW'>\n\t\t\t\t\t\tAruba\n\t\t\t\t\t<\/option><option value='AU'>\n\t\t\t\t\t\tAustralia\n\t\t\t\t\t<\/option><option value='AT'>\n\t\t\t\t\t\tAustria\n\t\t\t\t\t<\/option><option value='AZ'>\n\t\t\t\t\t\tAzerbaijan\n\t\t\t\t\t<\/option><option value='BS'>\n\t\t\t\t\t\tBahamas\n\t\t\t\t\t<\/option><option value='BH'>\n\t\t\t\t\t\tBahrain\n\t\t\t\t\t<\/option><option value='BD'>\n\t\t\t\t\t\tBangladesh\n\t\t\t\t\t<\/option><option value='BB'>\n\t\t\t\t\t\tBarbados\n\t\t\t\t\t<\/option><option value='BY'>\n\t\t\t\t\t\tBelarus\n\t\t\t\t\t<\/option><option value='BE'>\n\t\t\t\t\t\tBelgium\n\t\t\t\t\t<\/option><option value='BZ'>\n\t\t\t\t\t\tBelize\n\t\t\t\t\t<\/option><option value='BJ'>\n\t\t\t\t\t\tBenin\n\t\t\t\t\t<\/option><option value='BM'>\n\t\t\t\t\t\tBermuda\n\t\t\t\t\t<\/option><option value='BT'>\n\t\t\t\t\t\tBhutan\n\t\t\t\t\t<\/option><option value='BO'>\n\t\t\t\t\t\tBolivia\n\t\t\t\t\t<\/option><option value='BQ'>\n\t\t\t\t\t\tBonaire, Sint Eustatius and Saba\n\t\t\t\t\t<\/option><option value='BA'>\n\t\t\t\t\t\tBosnia and Herzegovina\n\t\t\t\t\t<\/option><option value='BW'>\n\t\t\t\t\t\tBotswana\n\t\t\t\t\t<\/option><option value='BV'>\n\t\t\t\t\t\tBouvet Island\n\t\t\t\t\t<\/option><option value='BR'>\n\t\t\t\t\t\tBrazil\n\t\t\t\t\t<\/option><option value='IO'>\n\t\t\t\t\t\tBritish Indian Ocean Territory\n\t\t\t\t\t<\/option><option value='BN'>\n\t\t\t\t\t\tBrunei Darussalam\n\t\t\t\t\t<\/option><option value='BG'>\n\t\t\t\t\t\tBulgaria\n\t\t\t\t\t<\/option><option value='BF'>\n\t\t\t\t\t\tBurkina Faso\n\t\t\t\t\t<\/option><option value='BI'>\n\t\t\t\t\t\tBurundi\n\t\t\t\t\t<\/option><option value='KH'>\n\t\t\t\t\t\tCambodia\n\t\t\t\t\t<\/option><option value='CM'>\n\t\t\t\t\t\tCameroon\n\t\t\t\t\t<\/option><option value='CA'>\n\t\t\t\t\t\tCanada\n\t\t\t\t\t<\/option><option value='CV'>\n\t\t\t\t\t\tCape Verde\n\t\t\t\t\t<\/option><option value='KY'>\n\t\t\t\t\t\tCayman Islands\n\t\t\t\t\t<\/option><option value='CF'>\n\t\t\t\t\t\tCentral African Republic\n\t\t\t\t\t<\/option><option value='TD'>\n\t\t\t\t\t\tChad\n\t\t\t\t\t<\/option><option value='CL'>\n\t\t\t\t\t\tChile\n\t\t\t\t\t<\/option><option value='CN'>\n\t\t\t\t\t\tChina\n\t\t\t\t\t<\/option><option value='CX'>\n\t\t\t\t\t\tChristmas Island\n\t\t\t\t\t<\/option><option value='CC'>\n\t\t\t\t\t\tCocos (Keeling) Islands\n\t\t\t\t\t<\/option><option value='CO'>\n\t\t\t\t\t\tColombia\n\t\t\t\t\t<\/option><option value='KM'>\n\t\t\t\t\t\tComoros\n\t\t\t\t\t<\/option><option value='CG'>\n\t\t\t\t\t\tCongo\n\t\t\t\t\t<\/option><option value='CD'>\n\t\t\t\t\t\tCongo, Democratic Republic of the Congo\n\t\t\t\t\t<\/option><option value='CK'>\n\t\t\t\t\t\tCook Islands\n\t\t\t\t\t<\/option><option value='CR'>\n\t\t\t\t\t\tCosta Rica\n\t\t\t\t\t<\/option><option value='CI'>\n\t\t\t\t\t\tCote D&#8217;Ivoire\n\t\t\t\t\t<\/option><option value='HR'>\n\t\t\t\t\t\tCroatia\n\t\t\t\t\t<\/option><option value='CU'>\n\t\t\t\t\t\tCuba\n\t\t\t\t\t<\/option><option value='CW'>\n\t\t\t\t\t\tCuracao\n\t\t\t\t\t<\/option><option value='CY'>\n\t\t\t\t\t\tCyprus\n\t\t\t\t\t<\/option><option value='CZ'>\n\t\t\t\t\t\tCzech Republic\n\t\t\t\t\t<\/option><option value='DK'>\n\t\t\t\t\t\tDenmark\n\t\t\t\t\t<\/option><option value='DJ'>\n\t\t\t\t\t\tDjibouti\n\t\t\t\t\t<\/option><option value='DM'>\n\t\t\t\t\t\tDominica\n\t\t\t\t\t<\/option><option value='DO'>\n\t\t\t\t\t\tDominican Republic\n\t\t\t\t\t<\/option><option value='EC'>\n\t\t\t\t\t\tEcuador\n\t\t\t\t\t<\/option><option value='EG'>\n\t\t\t\t\t\tEgypt\n\t\t\t\t\t<\/option><option value='SV'>\n\t\t\t\t\t\tEl Salvador\n\t\t\t\t\t<\/option><option value='GQ'>\n\t\t\t\t\t\tEquatorial Guinea\n\t\t\t\t\t<\/option><option value='ER'>\n\t\t\t\t\t\tEritrea\n\t\t\t\t\t<\/option><option value='EE'>\n\t\t\t\t\t\tEstonia\n\t\t\t\t\t<\/option><option value='ET'>\n\t\t\t\t\t\tEthiopia\n\t\t\t\t\t<\/option><option value='FK'>\n\t\t\t\t\t\tFalkland Islands (Malvinas)\n\t\t\t\t\t<\/option><option value='FO'>\n\t\t\t\t\t\tFaroe Islands\n\t\t\t\t\t<\/option><option value='FJ'>\n\t\t\t\t\t\tFiji\n\t\t\t\t\t<\/option><option value='FI'>\n\t\t\t\t\t\tFinland\n\t\t\t\t\t<\/option><option value='FR'>\n\t\t\t\t\t\tFrance\n\t\t\t\t\t<\/option><option value='GF'>\n\t\t\t\t\t\tFrench Guiana\n\t\t\t\t\t<\/option><option value='PF'>\n\t\t\t\t\t\tFrench Polynesia\n\t\t\t\t\t<\/option><option value='TF'>\n\t\t\t\t\t\tFrench Southern Territories\n\t\t\t\t\t<\/option><option value='GA'>\n\t\t\t\t\t\tGabon\n\t\t\t\t\t<\/option><option value='GM'>\n\t\t\t\t\t\tGambia\n\t\t\t\t\t<\/option><option value='GE'>\n\t\t\t\t\t\tGeorgia\n\t\t\t\t\t<\/option><option value='DE'>\n\t\t\t\t\t\tGermany\n\t\t\t\t\t<\/option><option value='GH'>\n\t\t\t\t\t\tGhana\n\t\t\t\t\t<\/option><option value='GI'>\n\t\t\t\t\t\tGibraltar\n\t\t\t\t\t<\/option><option value='GR'>\n\t\t\t\t\t\tGreece\n\t\t\t\t\t<\/option><option value='GL'>\n\t\t\t\t\t\tGreenland\n\t\t\t\t\t<\/option><option value='GD'>\n\t\t\t\t\t\tGrenada\n\t\t\t\t\t<\/option><option value='GP'>\n\t\t\t\t\t\tGuadeloupe\n\t\t\t\t\t<\/option><option value='GU'>\n\t\t\t\t\t\tGuam\n\t\t\t\t\t<\/option><option value='GT'>\n\t\t\t\t\t\tGuatemala\n\t\t\t\t\t<\/option><option value='GG'>\n\t\t\t\t\t\tGuernsey\n\t\t\t\t\t<\/option><option value='GN'>\n\t\t\t\t\t\tGuinea\n\t\t\t\t\t<\/option><option value='GW'>\n\t\t\t\t\t\tGuinea-Bissau\n\t\t\t\t\t<\/option><option value='GY'>\n\t\t\t\t\t\tGuyana\n\t\t\t\t\t<\/option><option value='HT'>\n\t\t\t\t\t\tHaiti\n\t\t\t\t\t<\/option><option value='HM'>\n\t\t\t\t\t\tHeard Island and Mcdonald Islands\n\t\t\t\t\t<\/option><option value='VA'>\n\t\t\t\t\t\tHoly See (Vatican City State)\n\t\t\t\t\t<\/option><option value='HN'>\n\t\t\t\t\t\tHonduras\n\t\t\t\t\t<\/option><option value='HK'>\n\t\t\t\t\t\tHong Kong\n\t\t\t\t\t<\/option><option value='HU'>\n\t\t\t\t\t\tHungary\n\t\t\t\t\t<\/option><option value='IS'>\n\t\t\t\t\t\tIceland\n\t\t\t\t\t<\/option><option value='IN'>\n\t\t\t\t\t\tIndia\n\t\t\t\t\t<\/option><option value='ID'>\n\t\t\t\t\t\tIndonesia\n\t\t\t\t\t<\/option><option value='IR'>\n\t\t\t\t\t\tIran, Islamic Republic of\n\t\t\t\t\t<\/option><option value='IQ'>\n\t\t\t\t\t\tIraq\n\t\t\t\t\t<\/option><option value='IE'>\n\t\t\t\t\t\tIreland\n\t\t\t\t\t<\/option><option value='IM'>\n\t\t\t\t\t\tIsle of Man\n\t\t\t\t\t<\/option><option value='IL'>\n\t\t\t\t\t\tIsrael\n\t\t\t\t\t<\/option><option value='IT'>\n\t\t\t\t\t\tItaly\n\t\t\t\t\t<\/option><option value='JM'>\n\t\t\t\t\t\tJamaica\n\t\t\t\t\t<\/option><option value='JP'>\n\t\t\t\t\t\tJapan\n\t\t\t\t\t<\/option><option value='JE'>\n\t\t\t\t\t\tJersey\n\t\t\t\t\t<\/option><option value='JO'>\n\t\t\t\t\t\tJordan\n\t\t\t\t\t<\/option><option value='KZ'>\n\t\t\t\t\t\tKazakhstan\n\t\t\t\t\t<\/option><option value='KE'>\n\t\t\t\t\t\tKenya\n\t\t\t\t\t<\/option><option value='KI'>\n\t\t\t\t\t\tKiribati\n\t\t\t\t\t<\/option><option value='KP'>\n\t\t\t\t\t\tKorea, Democratic People&#8217;s Republic of\n\t\t\t\t\t<\/option><option value='KR'>\n\t\t\t\t\t\tKorea, Republic of\n\t\t\t\t\t<\/option><option value='XK'>\n\t\t\t\t\t\tKosovo\n\t\t\t\t\t<\/option><option value='KW'>\n\t\t\t\t\t\tKuwait\n\t\t\t\t\t<\/option><option value='KG'>\n\t\t\t\t\t\tKyrgyzstan\n\t\t\t\t\t<\/option><option value='LA'>\n\t\t\t\t\t\tLao People&#8217;s Democratic Republic\n\t\t\t\t\t<\/option><option value='LV'>\n\t\t\t\t\t\tLatvia\n\t\t\t\t\t<\/option><option value='LB'>\n\t\t\t\t\t\tLebanon\n\t\t\t\t\t<\/option><option value='LS'>\n\t\t\t\t\t\tLesotho\n\t\t\t\t\t<\/option><option value='LR'>\n\t\t\t\t\t\tLiberia\n\t\t\t\t\t<\/option><option value='LY'>\n\t\t\t\t\t\tLibyan Arab Jamahiriya\n\t\t\t\t\t<\/option><option value='LI'>\n\t\t\t\t\t\tLiechtenstein\n\t\t\t\t\t<\/option><option value='LT'>\n\t\t\t\t\t\tLithuania\n\t\t\t\t\t<\/option><option value='LU'>\n\t\t\t\t\t\tLuxembourg\n\t\t\t\t\t<\/option><option value='MO'>\n\t\t\t\t\t\tMacao\n\t\t\t\t\t<\/option><option value='MK'>\n\t\t\t\t\t\tMacedonia, the Former Yugoslav Republic of\n\t\t\t\t\t<\/option><option value='MG'>\n\t\t\t\t\t\tMadagascar\n\t\t\t\t\t<\/option><option value='MW'>\n\t\t\t\t\t\tMalawi\n\t\t\t\t\t<\/option><option value='MY'>\n\t\t\t\t\t\tMalaysia\n\t\t\t\t\t<\/option><option value='MV'>\n\t\t\t\t\t\tMaldives\n\t\t\t\t\t<\/option><option value='ML'>\n\t\t\t\t\t\tMali\n\t\t\t\t\t<\/option><option value='MT'>\n\t\t\t\t\t\tMalta\n\t\t\t\t\t<\/option><option value='MH'>\n\t\t\t\t\t\tMarshall Islands\n\t\t\t\t\t<\/option><option value='MQ'>\n\t\t\t\t\t\tMartinique\n\t\t\t\t\t<\/option><option value='MR'>\n\t\t\t\t\t\tMauritania\n\t\t\t\t\t<\/option><option value='MU'>\n\t\t\t\t\t\tMauritius\n\t\t\t\t\t<\/option><option value='YT'>\n\t\t\t\t\t\tMayotte\n\t\t\t\t\t<\/option><option value='MX'>\n\t\t\t\t\t\tMexico\n\t\t\t\t\t<\/option><option value='FM'>\n\t\t\t\t\t\tMicronesia, Federated States of\n\t\t\t\t\t<\/option><option value='MD'>\n\t\t\t\t\t\tMoldova, Republic of\n\t\t\t\t\t<\/option><option value='MC'>\n\t\t\t\t\t\tMonaco\n\t\t\t\t\t<\/option><option value='MN'>\n\t\t\t\t\t\tMongolia\n\t\t\t\t\t<\/option><option value='ME'>\n\t\t\t\t\t\tMontenegro\n\t\t\t\t\t<\/option><option value='MS'>\n\t\t\t\t\t\tMontserrat\n\t\t\t\t\t<\/option><option value='MA'>\n\t\t\t\t\t\tMorocco\n\t\t\t\t\t<\/option><option value='MZ'>\n\t\t\t\t\t\tMozambique\n\t\t\t\t\t<\/option><option value='MM'>\n\t\t\t\t\t\tMyanmar\n\t\t\t\t\t<\/option><option value='NA'>\n\t\t\t\t\t\tNamibia\n\t\t\t\t\t<\/option><option value='NR'>\n\t\t\t\t\t\tNauru\n\t\t\t\t\t<\/option><option value='NP'>\n\t\t\t\t\t\tNepal\n\t\t\t\t\t<\/option><option value='NL'>\n\t\t\t\t\t\tNetherlands\n\t\t\t\t\t<\/option><option value='AN'>\n\t\t\t\t\t\tNetherlands Antilles\n\t\t\t\t\t<\/option><option value='NC'>\n\t\t\t\t\t\tNew Caledonia\n\t\t\t\t\t<\/option><option value='NZ'>\n\t\t\t\t\t\tNew Zealand\n\t\t\t\t\t<\/option><option value='NI'>\n\t\t\t\t\t\tNicaragua\n\t\t\t\t\t<\/option><option value='NE'>\n\t\t\t\t\t\tNiger\n\t\t\t\t\t<\/option><option value='NG'>\n\t\t\t\t\t\tNigeria\n\t\t\t\t\t<\/option><option value='NU'>\n\t\t\t\t\t\tNiue\n\t\t\t\t\t<\/option><option value='NF'>\n\t\t\t\t\t\tNorfolk Island\n\t\t\t\t\t<\/option><option value='MP'>\n\t\t\t\t\t\tNorthern Mariana Islands\n\t\t\t\t\t<\/option><option value='NO'>\n\t\t\t\t\t\tNorway\n\t\t\t\t\t<\/option><option value='OM'>\n\t\t\t\t\t\tOman\n\t\t\t\t\t<\/option><option value='PK'>\n\t\t\t\t\t\tPakistan\n\t\t\t\t\t<\/option><option value='PW'>\n\t\t\t\t\t\tPalau\n\t\t\t\t\t<\/option><option value='PS'>\n\t\t\t\t\t\tPalestinian Territory, Occupied\n\t\t\t\t\t<\/option><option value='PA'>\n\t\t\t\t\t\tPanama\n\t\t\t\t\t<\/option><option value='PG'>\n\t\t\t\t\t\tPapua New Guinea\n\t\t\t\t\t<\/option><option value='PY'>\n\t\t\t\t\t\tParaguay\n\t\t\t\t\t<\/option><option value='PE'>\n\t\t\t\t\t\tPeru\n\t\t\t\t\t<\/option><option value='PH'>\n\t\t\t\t\t\tPhilippines\n\t\t\t\t\t<\/option><option value='PN'>\n\t\t\t\t\t\tPitcairn\n\t\t\t\t\t<\/option><option value='PL'>\n\t\t\t\t\t\tPoland\n\t\t\t\t\t<\/option><option value='PT'>\n\t\t\t\t\t\tPortugal\n\t\t\t\t\t<\/option><option value='PR'>\n\t\t\t\t\t\tPuerto Rico\n\t\t\t\t\t<\/option><option value='QA'>\n\t\t\t\t\t\tQatar\n\t\t\t\t\t<\/option><option value='RE'>\n\t\t\t\t\t\tReunion\n\t\t\t\t\t<\/option><option value='RO'>\n\t\t\t\t\t\tRomania\n\t\t\t\t\t<\/option><option value='RU'>\n\t\t\t\t\t\tRussian Federation\n\t\t\t\t\t<\/option><option value='RW'>\n\t\t\t\t\t\tRwanda\n\t\t\t\t\t<\/option><option value='BL'>\n\t\t\t\t\t\tSaint Barthelemy\n\t\t\t\t\t<\/option><option value='SH'>\n\t\t\t\t\t\tSaint Helena\n\t\t\t\t\t<\/option><option value='KN'>\n\t\t\t\t\t\tSaint Kitts and Nevis\n\t\t\t\t\t<\/option><option value='LC'>\n\t\t\t\t\t\tSaint Lucia\n\t\t\t\t\t<\/option><option value='MF'>\n\t\t\t\t\t\tSaint Martin\n\t\t\t\t\t<\/option><option value='PM'>\n\t\t\t\t\t\tSaint Pierre and Miquelon\n\t\t\t\t\t<\/option><option value='VC'>\n\t\t\t\t\t\tSaint Vincent and the Grenadines\n\t\t\t\t\t<\/option><option value='WS'>\n\t\t\t\t\t\tSamoa\n\t\t\t\t\t<\/option><option value='SM'>\n\t\t\t\t\t\tSan Marino\n\t\t\t\t\t<\/option><option value='ST'>\n\t\t\t\t\t\tSao Tome and Principe\n\t\t\t\t\t<\/option><option value='SA'>\n\t\t\t\t\t\tSaudi Arabia\n\t\t\t\t\t<\/option><option value='SN'>\n\t\t\t\t\t\tSenegal\n\t\t\t\t\t<\/option><option value='RS'>\n\t\t\t\t\t\tSerbia\n\t\t\t\t\t<\/option><option value='CS'>\n\t\t\t\t\t\tSerbia and Montenegro\n\t\t\t\t\t<\/option><option value='SC'>\n\t\t\t\t\t\tSeychelles\n\t\t\t\t\t<\/option><option value='SL'>\n\t\t\t\t\t\tSierra Leone\n\t\t\t\t\t<\/option><option value='SG'>\n\t\t\t\t\t\tSingapore\n\t\t\t\t\t<\/option><option value='SX'>\n\t\t\t\t\t\tSint Maarten\n\t\t\t\t\t<\/option><option value='SK'>\n\t\t\t\t\t\tSlovakia\n\t\t\t\t\t<\/option><option value='SI'>\n\t\t\t\t\t\tSlovenia\n\t\t\t\t\t<\/option><option value='SB'>\n\t\t\t\t\t\tSolomon Islands\n\t\t\t\t\t<\/option><option value='SO'>\n\t\t\t\t\t\tSomalia\n\t\t\t\t\t<\/option><option value='ZA'>\n\t\t\t\t\t\tSouth Africa\n\t\t\t\t\t<\/option><option value='GS'>\n\t\t\t\t\t\tSouth Georgia and the South Sandwich Islands\n\t\t\t\t\t<\/option><option value='SS'>\n\t\t\t\t\t\tSouth Sudan\n\t\t\t\t\t<\/option><option value='ES'>\n\t\t\t\t\t\tSpain\n\t\t\t\t\t<\/option><option value='LK'>\n\t\t\t\t\t\tSri Lanka\n\t\t\t\t\t<\/option><option value='SD'>\n\t\t\t\t\t\tSudan\n\t\t\t\t\t<\/option><option value='SR'>\n\t\t\t\t\t\tSuriname\n\t\t\t\t\t<\/option><option value='SJ'>\n\t\t\t\t\t\tSvalbard and Jan Mayen\n\t\t\t\t\t<\/option><option value='SZ'>\n\t\t\t\t\t\tSwaziland\n\t\t\t\t\t<\/option><option value='SE'>\n\t\t\t\t\t\tSweden\n\t\t\t\t\t<\/option><option value='CH'>\n\t\t\t\t\t\tSwitzerland\n\t\t\t\t\t<\/option><option value='SY'>\n\t\t\t\t\t\tSyrian Arab Republic\n\t\t\t\t\t<\/option><option value='TW'>\n\t\t\t\t\t\tTaiwan\n\t\t\t\t\t<\/option><option value='TJ'>\n\t\t\t\t\t\tTajikistan\n\t\t\t\t\t<\/option><option value='TZ'>\n\t\t\t\t\t\tTanzania, United Republic of\n\t\t\t\t\t<\/option><option value='TH'>\n\t\t\t\t\t\tThailand\n\t\t\t\t\t<\/option><option value='TL'>\n\t\t\t\t\t\tTimor-Leste\n\t\t\t\t\t<\/option><option value='TG'>\n\t\t\t\t\t\tTogo\n\t\t\t\t\t<\/option><option value='TK'>\n\t\t\t\t\t\tTokelau\n\t\t\t\t\t<\/option><option value='TO'>\n\t\t\t\t\t\tTonga\n\t\t\t\t\t<\/option><option value='TT'>\n\t\t\t\t\t\tTrinidad and Tobago\n\t\t\t\t\t<\/option><option value='TN'>\n\t\t\t\t\t\tTunisia\n\t\t\t\t\t<\/option><option value='TR'>\n\t\t\t\t\t\tTurkey\n\t\t\t\t\t<\/option><option value='TM'>\n\t\t\t\t\t\tTurkmenistan\n\t\t\t\t\t<\/option><option value='TC'>\n\t\t\t\t\t\tTurks and Caicos Islands\n\t\t\t\t\t<\/option><option value='TV'>\n\t\t\t\t\t\tTuvalu\n\t\t\t\t\t<\/option><option value='UG'>\n\t\t\t\t\t\tUganda\n\t\t\t\t\t<\/option><option value='UA'>\n\t\t\t\t\t\tUkraine\n\t\t\t\t\t<\/option><option value='AE'>\n\t\t\t\t\t\tUnited Arab Emirates\n\t\t\t\t\t<\/option><option value='GB'>\n\t\t\t\t\t\tUnited Kingdom\n\t\t\t\t\t<\/option><option value='US'>\n\t\t\t\t\t\tUnited States\n\t\t\t\t\t<\/option><option value='UM'>\n\t\t\t\t\t\tUnited States Minor Outlying Islands\n\t\t\t\t\t<\/option><option value='UY'>\n\t\t\t\t\t\tUruguay\n\t\t\t\t\t<\/option><option value='UZ'>\n\t\t\t\t\t\tUzbekistan\n\t\t\t\t\t<\/option><option value='VU'>\n\t\t\t\t\t\tVanuatu\n\t\t\t\t\t<\/option><option value='VE'>\n\t\t\t\t\t\tVenezuela\n\t\t\t\t\t<\/option><option value='VN'>\n\t\t\t\t\t\tViet Nam\n\t\t\t\t\t<\/option><option value='VG'>\n\t\t\t\t\t\tVirgin Islands, British\n\t\t\t\t\t<\/option><option value='VI'>\n\t\t\t\t\t\tVirgin Islands, U.s.\n\t\t\t\t\t<\/option><option value='WF'>\n\t\t\t\t\t\tWallis and Futuna\n\t\t\t\t\t<\/option><option value='EH'>\n\t\t\t\t\t\tWestern Sahara\n\t\t\t\t\t<\/option><option value='YE'>\n\t\t\t\t\t\tYemen\n\t\t\t\t\t<\/option><option value='ZM'>\n\t\t\t\t\t\tZambia\n\t\t\t\t\t<\/option><option value='ZW'>\n\t\t\t\t\t\tZimbabwe\n\t\t\t\t\t<\/option>\t<\/select>\n\t\t                    <div class='w-full flex space-x-4 mb-4'>\n\t\t                       <div class='w-1\/2 flex-grow-0'>\n\t\t                            <input type='text' name='city' placeholder='City' class='w-full !outline-none p-c__md1 border-c_0.3 border-solid border-black box-border rounded-5' required=''>\n\t\t                    \t<\/div>\n\t\t                        <div class='w-1\/2 flex-grow-0'>\n\t\t                            <input type='text' name='state' placeholder='State' class='w-full !outline-none p-c__md1 border-c_0.3 border-solid border-black box-border rounded-5' required=''>\n\t\t                        <\/div>\n\t\t                    <\/div>\n\t\t                <\/div><div class='flex flex-col space-y-3 mb-1'>\n\t\t                <p class='text-lg text-gray-c_dark3 font-semibold'>Email Lists (please select at least one)<\/p>\n\t\t\t\t\t\t\t<div class='flex flex-col space-y-3 pl-10'>\n\t\t<div class='flex flex-row'>\n\t\t\t<input type='checkbox' id='nl0' value='1758116121' name='lists[]' class='newsletter_list mr-5 !outline-none'>\n\t\t\t<label for='nl0' class='text-lg text-gray-c_dark3 align-middle'>\n\t\t\t\tMedical\n\t\t\t<\/label>\n\t\t<\/div>\n\t\t\n\t\t<div class='flex flex-row'>\n\t\t\t<input type='checkbox' id='nl1' value='1005694041' name='lists[]' class='newsletter_list mr-5 !outline-none'>\n\t\t\t<label for='nl1' class='text-lg text-gray-c_dark3 align-middle'>\n\t\t\t\tNuclear Medicine\n\t\t\t<\/label>\n\t\t<\/div>\n\t\t\n\t\t<div class='flex flex-row'>\n\t\t\t<input type='checkbox' id='nl2' value='1455120706' name='lists[]' class='newsletter_list mr-5 !outline-none'>\n\t\t\t<label for='nl2' class='text-lg text-gray-c_dark3 align-middle'>\n\t\t\t\tRadiation Therapy\n\t\t\t<\/label>\n\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div><div class='container mx-auto relative h-10'>\n\t\t                    <i class='absolute inset-x-0 w-2 mx-auto bottom-5 transform rotate-45 inline-block p-1 rounded-1.5 border-solid border-gray-c_dark border-r-2 border-b-2'><\/i>\n\t\t                <\/div>\n\t\t                <div class='flex flex-row items-center w-full px-4 py-1.5 border-c_0.3 border-black border-solid box-border rounded-5 bg-white'>\n\t\t                    <input id='confirm' name='privacy' type='checkbox' class='mr-5 !outline-none' required=''>\n\t\t                    <label for='confirm' class='text-base text-gray-c_dark align-middle'>By clicking subscribe, you give your consent to join our mailing list, to receive the Medical BulletIn and for processing your personal data in accordance with our <a href=\"https:\/\/medical.ezag.com\/en\/data-privacy-policy\/\" target=\"_blank\">Data Privacy Statement<\/a>.<\/label>\n\t\t                <\/div>\n\t\t\n\t\t                <div class='w-full flex-1 flex space-x-4 mt-3.5'><div class='g-recaptcha' data-callback='validateNewsletter' data-expired-callback='newsletterCaptchaExpired' data-sitekey='6LcjcmsdAAAAAJe1iUClMrb83EFyLrzrcBtKROrb'><\/div>\n\t\t                    <button disabled class='w-1\/2 flex-1 bg-red hover:bg-red-20p_darker rounded-5 text-white text-lg w-full py-3 disabled:bg-gray-c_light' id='subscribe_to_newsletter_btn'>Subscribe<\/button>\n\t\t                <\/div>\n\t\t\t\t<\/form>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<section class='newsletter-sign-up mx-auto w-full py-14 bg-gray-c_bright3 px-4 tablet:px-0' >\n\t\t\t\t<div class='flex flex-col md:!flex-row  mx-auto max-w-5xl  items-center'>\n\t\t\t\t\t<p class='w-full md:w-auto text-center md:text-left md:flex-grow-0 pr-0 md:pr-8 font-bold text-blue-100 text-c_md4'>\n\t\t\t\t\t\tSUBSCRIBE TO OUR NEWSLETTER\n\t\t\t\t\t<\/p>\n\t\t\t\t\t<div class='w-full md:w-auto md:flex-grow mt-6 md:!mt-0'>\n\t\t\t\t\t\t<div class='flex'>\n\t\t\t\t\t\t\t<div class='p-4 w-full border-c_0.3 border-black border-solid box-border bg-white rounded-5-l h-c_md2'>\n\t\t\t\t\t\t\t\t<input id='newsletter_email_pre_input' class='w-full !outline-none' name='pre_newsletter_email' type='email' placeholder='Enter your Email'\/>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<button class='flex-grow-0 bg-blue-100 px-3 rounded-5-r h-c_md2' id='initial_newsletter_su_btn' aria-label='SUBSCRIBE TO OUR NEWSLETTER'>\n\t\t\t\t\t\t\t    <svg xmlns='http:\/\/www.w3.org\/2000\/svg' class='w-auto h-8' width='66' height='44' viewBox='0 0 66 44'>\n\t\t\t\t\t\t\t        <g fill='#FFF' fill-rule='evenodd' transform='translate(.384 .548)'>\n\t\t\t\t\t\t\t            <path d='M0.635095468,7.654862 C30.8179444,3.4431028 32.8923481,3.27110682 63.6042263,0.0153346225 C65.1349281,-0.146935373 65.6326662,1.0113811 64.926709,1.9413595 C49.7361781,21.9522958 49.0524185,22.1869234 33.6242091,42.3916265 C33.1587372,43.0012061 32.0474927,42.9628075 31.5133431,42.3916265 C24.7653811,35.1758435 25.1162461,35.4028429 18.2274843,28.3302607 C17.5055085,27.6036209 17.0547445,26.7062303 18.2274843,26.2008105 C32.0275989,18.5620696 32.8571969,18.2922478 45.8914694,10.8406293 C46.9805696,10.1708609 46.5581561,8.76751478 44.5611574,9.61584359 C34.6083296,13.6672433 24.4862031,18.3763253 14.1947779,23.7430897 C13.1866861,27.0296322 12.2264954,30.1471963 11.3142057,33.0957821 C11.2181062,33.4063826 10.6744628,33.4496806 10.6497756,33.0957821 C10.1703081,26.2224772 10.1703081,26.3581066 9.96283349,19.3606853 C5.49909146,14.660254 5.20046758,14.310999 0.635095468,9.61584359 C-0.269984235,8.76188388 -0.151337284,7.92698876 0.635095468,7.654862 Z'\/><path d='M16.1540773,30.5818018 C16.334513,29.8560137 17.187486,29.6614869 17.6742305,30.253422 C19.5543367,32.4098479 19.8144883,32.7165823 21.7887415,34.9067345 C22.2265749,35.3924482 22.1381486,35.8587772 21.5286181,36.1252589 C18.7524173,37.3389909 18.1504291,37.6974386 15.3536243,38.8712091 C14.6417771,39.0227704 13.9928847,38.6476287 14.0682984,37.8560542 C15.0189286,34.3311311 15.3330562,33.8842926 16.1540773,30.5818018 Z'\/>\n\t\t\t\t\t\t\t        <\/g>\n                                   <\/svg>\n\t\t\t\t\t\t\t<\/button>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n            <\/section>\n\t\t","protected":false},"excerpt":{"rendered":"Berlin, 9 February 2022. Eckert &#038; Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert &#038; Ziegler&#8217;s therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix&#8217;s portfolio of Molecularly Targeted Radiation (MTR) investigational products.\n\nEZAG will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix&#8217;s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer).\n\nLutetium-177 is used in precision oncology for targeted radionuclide therapy. The radioisotope Lutetium-177, is linked to tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells, while largely sparing healthy tissue.\n\n&#8220;The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services,&#8221; explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert &#038; Ziegler. &#8220;Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.&#8221;\n\nDr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, &#8220;We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who are now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix&#8217;s relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.&#8221;\n\nRadiotherapeutic agents that are coupled with Lutetium-177 prior to injection are currently under late-stage clinical development for several types of cancer.\n\nAbout Eckert &#038; Ziegler.\nEckert &#038; Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world&#8217;s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert &#038; Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B\u00f6rse.\nContributing to saving lives.\n\nAbout Telix Pharmaceuticals\nTelix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).","protected":false},"featured_media":4659,"template":"","meta":{"content-type":"","place":"Berlin","news_date":"2022-02-09T08:26:00","primary-contact":"","secondary-contact":"","footnotes":""},"news-business-unit":[5],"class_list":["post-5068","news","type-news","status-publish","has-post-thumbnail","hentry","news-business-unit-radiopharma"],"formatted_date":"February 9, 2022","ez_date":"2022-02-09T08:26:00","yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eckert &amp; Ziegler to Supply Telix with Lutetium-177 for Clinical Trials | Eckert &amp; Ziegler Medical<\/title>\n<meta name=\"description\" content=\"Berlin, 9 February 2022. Eckert &amp; Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert &amp; Ziegler&#039;s therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix&#039;s portfolio of Molecularly Targeted Radiation (MTR) investigational products. EZAG will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix&#039;s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer). Lutetium-177 is used in precision oncology for targeted radionuclide therapy. The radioisotope Lutetium-177, is linked to tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells, while largely sparing healthy tissue. &quot;The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services,&quot; explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert &amp; Ziegler. &quot;Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.&quot; Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, &quot;We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who are now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix&#039;s relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.&quot; Radiotherapeutic agents that are coupled with Lutetium-177 prior to injection are currently under late-stage clinical development for several types of cancer. About Eckert &amp; Ziegler. Eckert &amp; Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world&#039;s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert &amp; Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B\u00f6rse. Contributing to saving lives. About Telix Pharmaceuticals Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eckert &amp; Ziegler to Supply Telix with Lutetium-177 for Clinical Trials | Eckert &amp; Ziegler Medical\" \/>\n<meta property=\"og:description\" content=\"Berlin, 9 February 2022. Eckert &amp; Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert &amp; Ziegler&#039;s therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix&#039;s portfolio of Molecularly Targeted Radiation (MTR) investigational products. EZAG will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix&#039;s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer). Lutetium-177 is used in precision oncology for targeted radionuclide therapy. The radioisotope Lutetium-177, is linked to tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells, while largely sparing healthy tissue. &quot;The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services,&quot; explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert &amp; Ziegler. &quot;Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.&quot; Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, &quot;We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who are now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix&#039;s relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.&quot; Radiotherapeutic agents that are coupled with Lutetium-177 prior to injection are currently under late-stage clinical development for several types of cancer. About Eckert &amp; Ziegler. Eckert &amp; Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world&#039;s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert &amp; Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B\u00f6rse. Contributing to saving lives. About Telix Pharmaceuticals Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&amp;cHash=394221eae6de9ebffddc6b4e427ddd2a\" \/>\n<meta property=\"og:site_name\" content=\"Eckert &amp; Ziegler Medical\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-14T07:15:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medical.ezag.com\/wp-content\/uploads\/2021\/06\/Telix-neu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medical.ezag.com\/en\/news\/eckert-ziegler-to-supply-telix-with-lutetium-177-for-clinical-trials\/\",\"url\":\"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a\",\"name\":\"Eckert & Ziegler to Supply Telix with Lutetium-177 for Clinical Trials | Eckert &amp; Ziegler Medical\",\"isPartOf\":{\"@id\":\"https:\/\/medical.ezag.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medical.ezag.com\/wp-content\/uploads\/2021\/06\/Telix-neu.png\",\"datePublished\":\"2022-02-09T08:26:31+00:00\",\"dateModified\":\"2022-04-14T07:15:14+00:00\",\"description\":\"Berlin, 9 February 2022. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert & Ziegler's therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix's portfolio of Molecularly Targeted Radiation (MTR) investigational products. EZAG will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix's therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer). Lutetium-177 is used in precision oncology for targeted radionuclide therapy. The radioisotope Lutetium-177, is linked to tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells, while largely sparing healthy tissue. \\\"The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services,\\\" explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. \\\"Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.\\\" Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, \\\"We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who are now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix's relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.\\\" Radiotherapeutic agents that are coupled with Lutetium-177 prior to injection are currently under late-stage clinical development for several types of cancer. About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B\u00f6rse. Contributing to saving lives. About Telix Pharmaceuticals Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#primaryimage\",\"url\":\"https:\/\/medical.ezag.com\/wp-content\/uploads\/2021\/06\/Telix-neu.png\",\"contentUrl\":\"https:\/\/medical.ezag.com\/wp-content\/uploads\/2021\/06\/Telix-neu.png\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medical.ezag.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eckert &#038; Ziegler to Supply Telix with Lutetium-177 for Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medical.ezag.com\/en\/#website\",\"url\":\"https:\/\/medical.ezag.com\/en\/\",\"name\":\"Eckert & Ziegler Medical\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/medical.ezag.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medical.ezag.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/medical.ezag.com\/en\/#organization\",\"name\":\"Eckert & Ziegler Medical\",\"url\":\"https:\/\/medical.ezag.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medical.ezag.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/medical.ezag.com\/wp-content\/uploads\/2022\/05\/Org.png\",\"contentUrl\":\"https:\/\/medical.ezag.com\/wp-content\/uploads\/2022\/05\/Org.png\",\"width\":776,\"height\":613,\"caption\":\"Eckert & Ziegler Medical\"},\"image\":{\"@id\":\"https:\/\/medical.ezag.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/showcase\/ez-medical\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eckert & Ziegler to Supply Telix with Lutetium-177 for Clinical Trials | Eckert &amp; Ziegler Medical","description":"Berlin, 9 February 2022. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert & Ziegler's therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix's portfolio of Molecularly Targeted Radiation (MTR) investigational products. EZAG will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix's therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer). Lutetium-177 is used in precision oncology for targeted radionuclide therapy. The radioisotope Lutetium-177, is linked to tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells, while largely sparing healthy tissue. \"The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services,\" explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. \"Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.\" Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, \"We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who are now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix's relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.\" Radiotherapeutic agents that are coupled with Lutetium-177 prior to injection are currently under late-stage clinical development for several types of cancer. About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B\u00f6rse. Contributing to saving lives. About Telix Pharmaceuticals Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a","og_locale":"en_US","og_type":"article","og_title":"Eckert & Ziegler to Supply Telix with Lutetium-177 for Clinical Trials | Eckert &amp; Ziegler Medical","og_description":"Berlin, 9 February 2022. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert & Ziegler's therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix's portfolio of Molecularly Targeted Radiation (MTR) investigational products. EZAG will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix's therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer). Lutetium-177 is used in precision oncology for targeted radionuclide therapy. The radioisotope Lutetium-177, is linked to tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells, while largely sparing healthy tissue. \"The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services,\" explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. \"Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.\" Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, \"We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who are now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix's relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.\" Radiotherapeutic agents that are coupled with Lutetium-177 prior to injection are currently under late-stage clinical development for several types of cancer. About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B\u00f6rse. Contributing to saving lives. About Telix Pharmaceuticals Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).","og_url":"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a","og_site_name":"Eckert &amp; Ziegler Medical","article_modified_time":"2022-04-14T07:15:14+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/medical.ezag.com\/wp-content\/uploads\/2021\/06\/Telix-neu.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/medical.ezag.com\/en\/news\/eckert-ziegler-to-supply-telix-with-lutetium-177-for-clinical-trials\/","url":"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a","name":"Eckert & Ziegler to Supply Telix with Lutetium-177 for Clinical Trials | Eckert &amp; Ziegler Medical","isPartOf":{"@id":"https:\/\/medical.ezag.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#primaryimage"},"image":{"@id":"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#primaryimage"},"thumbnailUrl":"https:\/\/medical.ezag.com\/wp-content\/uploads\/2021\/06\/Telix-neu.png","datePublished":"2022-02-09T08:26:31+00:00","dateModified":"2022-04-14T07:15:14+00:00","description":"Berlin, 9 February 2022. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with Telix Pharmaceuticals Limited (ASX:TLX, Telix) a comprehensive global supply agreement for Eckert & Ziegler's therapeutic radioisotope Lutetium-177 (non-carrier-added 177Lu). The radiopharmaceutical will be used to advance Telix's portfolio of Molecularly Targeted Radiation (MTR) investigational products. EZAG will immediately commence supply of n.c.a. 177Lu for use in clinical trials of Telix's therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer). Lutetium-177 is used in precision oncology for targeted radionuclide therapy. The radioisotope Lutetium-177, is linked to tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells, while largely sparing healthy tissue. \"The agreement underlines our outstanding expertise in delivering isotopes to the pharmaceutical industry. With our production facilities in Europe, Asia and in North America, we are excellently positioned to meet the increasing demand for this isotope and related development and manufacturing services,\" explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. \"Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.\" Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, \"We are pleased to have established this agreement with EZAG, a premier supplier of high-quality medical radioisotopes, who are now part of our global network of lutetium suppliers. We are committed to working with global partners with a reputation for delivering the highest quality isotopes, and a demonstrated commitment to environmentally sustainable production technologies. Telix's relationship with EZAG is a multi-isotope partnership and we are delighted to include 177Lu access as part of the supply chain.\" Radiotherapeutic agents that are coupled with Lutetium-177 prior to injection are currently under late-stage clinical development for several types of cancer. About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B\u00f6rse. Contributing to saving lives. About Telix Pharmaceuticals Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).","breadcrumb":{"@id":"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#primaryimage","url":"https:\/\/medical.ezag.com\/wp-content\/uploads\/2021\/06\/Telix-neu.png","contentUrl":"https:\/\/medical.ezag.com\/wp-content\/uploads\/2021\/06\/Telix-neu.png","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.ezag.com\/home\/press\/press_releases\/detail\/?tx_ttnews%5btt_news%5d=1674&cHash=394221eae6de9ebffddc6b4e427ddd2a#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medical.ezag.com\/en\/"},{"@type":"ListItem","position":2,"name":"Eckert &#038; Ziegler to Supply Telix with Lutetium-177 for Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/medical.ezag.com\/en\/#website","url":"https:\/\/medical.ezag.com\/en\/","name":"Eckert & Ziegler Medical","description":"","publisher":{"@id":"https:\/\/medical.ezag.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medical.ezag.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/medical.ezag.com\/en\/#organization","name":"Eckert & Ziegler Medical","url":"https:\/\/medical.ezag.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medical.ezag.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/medical.ezag.com\/wp-content\/uploads\/2022\/05\/Org.png","contentUrl":"https:\/\/medical.ezag.com\/wp-content\/uploads\/2022\/05\/Org.png","width":776,"height":613,"caption":"Eckert & Ziegler Medical"},"image":{"@id":"https:\/\/medical.ezag.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/showcase\/ez-medical"]}]}},"_links":{"self":[{"href":"https:\/\/medical.ezag.com\/en\/wp-json\/wp\/v2\/news\/5068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medical.ezag.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/medical.ezag.com\/en\/wp-json\/wp\/v2\/types\/news"}],"version-history":[{"count":7,"href":"https:\/\/medical.ezag.com\/en\/wp-json\/wp\/v2\/news\/5068\/revisions"}],"predecessor-version":[{"id":5083,"href":"https:\/\/medical.ezag.com\/en\/wp-json\/wp\/v2\/news\/5068\/revisions\/5083"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medical.ezag.com\/en\/wp-json\/wp\/v2\/media\/4659"}],"wp:attachment":[{"href":"https:\/\/medical.ezag.com\/en\/wp-json\/wp\/v2\/media?parent=5068"}],"wp:term":[{"taxonomy":"news-business-unit","embeddable":true,"href":"https:\/\/medical.ezag.com\/en\/wp-json\/wp\/v2\/news-business-unit?post=5068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}